Open AccessPhase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Author(s) -
Claire Harrison,
Vikas Gupta,
Aaron T. Gerds,
Raajit K. Rampal,
Srđan Verstovšek,
Moshe Talpaz,
JeanJacques Kiladjian,
Ruben A. Mesa,
Andrew Kuykendall,
Alessandro M. Vannucchi,
Francesca Palandri,
Sebastian Grosicki,
Timothy Devos,
Éric Jourdan,
Mariëlle J. Wondergem,
Haifa Kathrin Al-Ali,
Veronika BuxhoferAusch,
Alberto ÁlvarezLarrán,
Andrea Patriarca,
Marina Kremyanskaya,
Adam J. Mead,
Sanjay Akhani,
Yuri Sheikine,
Gozde Colak,
John Mascarenhas
Publication year - 2022
Publication title -
future oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0484
Subject(s) - ruxolitinib , medicine , myelofibrosis , clinical trial , myeloproliferative neoplasm , anemia , oncology , bone marrow , placebo , surgery , pathology , alternative medicine